Announcements
- Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
- Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
- European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
- Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
- Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
- Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
- Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
- Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
- Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
- Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
More ▼
Key statistics
On Tuesday, Scinai Immunotherapeutics Ltd (2F5:FRA) closed at 3.12, 4.70% above its 52-week low of 2.98, set on Jun 17, 2024.
52-week range
Open | 3.04 |
---|---|
High | 3.12 |
Low | 3.04 |
Bid | 2.68 |
Offer | 3.04 |
Previous close | 3.00 |
Average volume | 1.96k |
---|---|
Shares outstanding | 150.00 |
Free float | -- |
P/E (TTM) | -- |
Market cap | 1.95m USD |
EPS (TTM) | -231.24 USD |
Data delayed at least 15 minutes, as of Jun 25 2024 14:29 BST.
More ▼